TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $10.32M |
| Net Income (Most Recent Fiscal Year) | $-129.77M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.30 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.63 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1360.61% |
| Net Margin (Trailing 12 Months) | -1360.61% |
| Return on Equity (Trailing 12 Months) | -91.94% |
| Return on Assets (Trailing 12 Months) | -50.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.34 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.22 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.96 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 65.35M |
| Free Float | 61.27M |
| Market Capitalization | $66.66M |
| Average Volume (Last 20 Days) | 0.73M |
| Beta (Past 60 Months) | 1.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.25% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |